| Source: HalifaxProj(inhibit) |
| Type: |
| NF-kB signaling Nuclear factor kappa B (NF-κB) is a transcription factor that plays a crucial role in regulating immune response, inflammation, cell proliferation, and survival. NF-κB is often found to be constitutively active in many types of cancer cells. This persistent activation can promote tumorigenesis by enhancing cell survival, proliferation, and metastasis. |
| 3588- | CUR, | The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies |
| - | Review, | AD, | NA |
| 3581- | CUR, | Curcumin Attenuated Neurotoxicity in Sporadic Animal Model of Alzheimer's Disease |
| - | NA, | AD, | NA |
| 3574- | CUR, | The effect of curcumin (turmeric) on Alzheimer's disease: An overview |
| - | Review, | AD, | NA |
| 4831- | CUR, | The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity |
| - | in-vitro, | NA, | NA |
| 4826- | CUR, | The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management |
| - | Review, | Var, | NA |
| 4828- | CUR, | Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane) |
| - | Review, | Var, | NA |
| 4652- | CUR, | Anticancer effect of curcumin on breast cancer and stem cells |
| - | Review, | BC, | NA |
| 4656- | CUR, | EGCG, | Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 |
| 4671- | CUR, | Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy |
| - | in-vitro, | CRC, | NA |
| 2308- | CUR, | Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells |
| - | in-vitro, | Liver, | HepG2 |
| 2466- | CUR, | Regulatory Effects of Curcumin on Platelets: An Update and Future Directions |
| - | Review, | Nor, | NA |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2819- | CUR, | Chemo, | Curcumin as a hepatoprotective agent against chemotherapy-induced liver injury |
| - | Review, | Var, | NA |
| 2818- | CUR, | Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways |
| - | Review, | AD, | NA |
| 2814- | CUR, | Curcumin in Cancer and Inflammation: An In-Depth Exploration of Molecular Interactions, Therapeutic Potentials, and the Role in Disease Management |
| - | Review, | Var, | NA |
| 2816- | CUR, | NEUROPROTECTIVE EFFECTS OF CURCUMIN |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2980- | CUR, | Inhibition of NF B and Pancreatic Cancer Cell and Tumor Growth by Curcumin Is Dependent on Specificity Protein Down-regulation |
| - | in-vivo, | PC, | NA |
| 2976- | CUR, | Curcumin suppresses the proliferation of oral squamous cell carcinoma through a specificity protein 1/nuclear factor‑κB‑dependent pathway |
| - | in-vitro, | Oral, | HSC3 | - | in-vitro, | HNSCC, | CAL33 |
| 2974- | CUR, | Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT15 | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | SW-620 | - | in-vivo, | NA, | NA |
| 6235- | CUSP9, | Exhaustive in vitro evaluation of the 9-drug cocktail CUSP9 for treatment of glioblastoma |
| - | in-vitro, | GBM, | NA |
| - | NA, | GBM, | NA |
| 6246- | Cyc, | Cyclopamine is a novel Hedgehog signaling inhibitor with significant anti-proliferative, anti-invasive and anti-estrogenic potency in human breast cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 7452- | CYN, | Cynaropicrin inhibits pancreatic cancer cell viability and disrupts cellular redox homeostasis |
| - | in-vitro, | PC, | PANC1 |
| 7451- | CYN, | Inhibitory effects of cynaropicrin on human melanoma progression by targeting MAPK, NF‐κB, and Nrf‐2 signaling pathways in vitro |
| - | in-vitro, | Melanoma, | A375 |
| 7447- | CYN, | Antiproliferative Effects of Cynaropicrin on Anaplastic Thyroid Cancer Cells |
| - | in-vitro, | Thyroid, | 8505C | - | in-vitro, | Thyroid, | CAL62 | - | in-vitro, | Thyroid, | SW1736 |
| 7444- | CYN, | The Sesquiterpene Lactone Cynaropicrin Manifests Strong Cytotoxicity in Glioblastoma Cells U-87 MG by Induction of Oxidative Stress |
| - | in-vitro, | GBM, | U87MG |
| 1442- | Deg, | Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention |
| - | Review, | Var, | NA |
| 1443- | Deg, | Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | BC, | BT549 |
| 6676- | Deg, | Deguelin’s Anticancer Bioactivity: Challenges and Opportunities in Medicinal Chemistry |
| - | Review, | Var, | NA |
| 6672- | Deg, | Deguelin, an Akt inhibitor, down-regulates NF-κB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice |
| - | vitro+vivo, | CRC, | COLO205 | - | in-vitro, | CRC, | HCT116 |
| 19- | Deg, | Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 |
| 6705- | DFC, | Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases |
| - | Review, | Var, | NA |
| 6748- | DHA, | Docosahexaenoic acid enrichment of tumor phospholipid membranes increases tumor necroptosis in mice bearing triple negative breast cancer patient-derived xenografts |
| - | in-vivo, | BC, | NA |
| 1085- | DHA, | EPA, | DHA and EPA Down-regulate COX-2 Expression through Suppression of NF-kappaB Activity in LPS-treated Human Umbilical Vein Endothelial Cells |
| - | in-vitro, | Nor, | HUVECs |
| 6729- | Dipy, | Dipyridamole prevents triple-negative breast-cancer progression |
| - | Trial, | BC, | MDA-MB-231 |
| 6287- | DL, | D-Limonene Is a Potential Monoterpene to Inhibit PI3K/Akt/IKK-α/NF-κB p65 Signaling Pathway in Coronavirus Disease 2019 Pulmonary Fibrosis |
| - | in-vivo, | Covid, | NA |
| 6282- | DL, | Limonene Exerts Anti-Inflammatory Effect on LPS-Induced Jejunal Injury in Mice by Inhibiting NF-κB/AP-1 Pathway |
| - | in-vivo, | IBD, | NA |
| 6349- | DRE, | Dandelion root extract protects NCM460 colonic cells and relieves experimental mouse colitis |
| - | vitro+vivo, | Nor, | NCM460 |
| 6318- | DRE, | Dandelion root extract affects colorectal cancer proliferation and survival through the activation of multiple death signalling pathways |
| - | vitro+vivo, | CRC, | HCT116 | - | NA, | Nor, | NCM460 |
| 6353- | DRE, | Cisplatin, | Insights Into Protective Mechanisms of Dandelion Leaf Extract Against Cisplatin-Induced Nephrotoxicity in Rats: Role of Inhibitory Effect on Inflammatory and Apoptotic Pathways |
| - | in-vivo, | Nor, | NA |
| 6358- | DRE, | Dandelion root extracts and taraxasterol inhibit LPS‑induced colorectal cancer cell viability by blocking TLR4‑NFκB‑driven ACE2 and TMPRSS2 pathways |
| - | in-vitro, | CRC, | NA |
| 6359- | DRE, | Natural Health Products (NHP’s) and Natural Compounds as Therapeutic Agents for the Treatment of Cancer; Mechanisms of Anti-Cancer Activity of Natural Compounds and Overall Trends |
| - | Review, | Var, | NA |
| 6363- | DRE, | Therapeutic Potential of Dandelion (Taraxacum officinale) Root Extract in Colon Cancer: A Comprehensive Review |
| - | in-vitro, | CRC, | NA |
| 6744- | DSF, | Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | T47D |
| 4914- | DSF, | immuno, | Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies |
| - | Review, | Var, | NA |
| 4916- | DSF, | Cu, | The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics |
| - | Review, | Var, | NA |
| 4915- | DSF, | Cu, | Disulfiram: A novel repurposed drug for cancer therapy |
| - | Review, | Var, | NA |
| 5008- | DSF, | Cu, | Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis |
| - | in-vitro, | HCC, | NA |
| 5012- | DSF, | Cu, | Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:214 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid